Page 18 - Haematologica Vol. 110 - January 2025

PROS AND CONS EDITORIAL
Y. Ofran and J.M. Rowe
2024;11(5):e324-e335.
4. Schmid C, Schleuning M, Ledderose G, Tischer J, Kolb HJ.
Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome. J Clin Oncol. 2005;23(24):5675-5687.
5. Schmid C, Schleuning M, Schwerdtfeger R, et al. Long-term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem cell transplantation. Blood. 2006;108(3):1092-1099.
6. Copelan E, Gale RP. Haematopoietic cell transplantation soon after first relapse in acute myeloid leukaemia. Haematologica. 2025;110(1):4-6.
7. MacCallum PK, Davis CL, Rohatiner AZ, et al. Mitoxantrone and cytosine arabinoside as treatment for acute myelogenous leukemia (AML) at first recurrence. Leukemia. 1993;7(10):1496-1499.
8. Karanes C, Kopecky KJ, Head DR, et al. A phase III comparison of high dose ARA-C (HIDAC) versus HIDAC plus mitoxantrone in the treatment of first relapsed or refractory acute myeloid leukemia southwest oncology group study. Leuk Res. 1999;23(9):787-794.
9. Raanani P, Shpilberg O, Gillis S, et al. Salvage therapy of refractory and relapsed acute leukemia with high dose mitoxantrone and high dose cytarabine. Leuk Res. 1999;23(8):695-700.
10. Canaani J, Nagar M, Heering G, et al. Reassessing the role of high dose cytarabine and mitoxantrone in relapsed / refractory acute myeloid leukemia. Oncotarget. 2020;11(23):2233-2245.
11. Zhong S, Kurish H, Walchack R, et al. Efficacy and safety of mitoxantrone, etoposide, and cytarabine for treatment of relapsed or refractory acute myeloid leukemia. Leuk Res. 2024;139:107468.
12. Walter RB, Gooley TA, Wood BL, et al. Impact of pretransplantation minimal residual disease, as detected by multiparametric flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute myeloid leukemia. J Clin Oncol. 2011;29(9):1190-1197.
13. Weisdorf DJ, Millard HR, Horowitz MM, et al. Allogeneic transplantation for advanced acute myeloid leukemia: the value of complete remission. Cancer. 2017;123(11):2025-2034.
14. Yanada M, Yamasaki S, Kondo T, et al. Allogeneic hematopoietic cell transplantation for patients with acute myeloid leukemia not in remission. Leukemia. 2024;38(3):513-520.
15. Nagler A, Ngoya M, Galimard JE, et al. Longitudinal outcome over two decades of unrelated allogeneic stem cell transplantation for relapsed / refractory acute myeloid leukemia: an ALWP/EBMT analysis. Clin Cancer Res. 2022;28(19):4258-4266.
16. de Botton S, Fenaux P, Yee K, et al. Olutasidenib (FT-2102)
induces durable complete remissions in patients with relapsed
or refractory IDH1-mutated AML. Blood Adv. 2023;7(13):3117-3127. 17. DiNardo CD, Stein EM, de Botton S, et al. Durable remissions
with ivosidenib in IDH1-mutated relapsed or refractory AML. N
Engl J Med. 2018;378(25):2386-2398.
18. Stein EM, DiNardo CD, Pollyea DA, et al. Enasidenib in mutant
IDH2 relapsed or refractory acute myeloid leukemia. Blood.
2017;130(6):722-731.
19. Perl AE, Larson RA, Podoltsev NA, et al. Follow-up of patients
with R/R FLT3-mutation-positive AML treated with gilteritinib in
the phase 3 ADMIRAL trial. Blood. 2022;139(23):3366-3375. 20. Döhner H, Estey E, Grimwade D, et al. Diagnosis and
management of AML in adults: 2017 ELN recommendations from
an international expert panel. Blood. 2017;129(4):424-447.
21. Blachly JS, Walter RB, Hourigan CS. The present and future of
measurable residual disease testing in acute myeloid leukemia.
Haematologica. 2022;107(12):2810-2822.
22. Ronnacker J, Urbahn MA, Reicherts C, et al. Early blast
clearance during sequential conditioning prior to allogeneic stem cell transplantation in patients with acute myeloid leukaemia. Br J Haematol. 2024;205(1):280-290.
23. Song KW, Lipton J. Is it appropriate to offer allogeneic hematopoietic stem cell transplantation to patients with primary refractory acute myeloid leukemia? Bone Marrow Transplant. 2005;36(3):183-191.
24. Paras G, Morsink LM, Othus M, et al. Conditioning intensity and peritransplant flow cytometric MRD dynamics in adult AML. Blood. 2022;139(11):1694-1706.
25. Bataller A, Kantarjian H, Bazinet A, et al. Outcomes and genetic dynamics of acute myeloid leukemia at first relapse. Heamatologica. Haematologica. 2024;109(11):3543-3556
26. Ganzel C, Ram R, Gural A, et al. Venetoclax is safe and efficacious in relapsed / refractory AML. Leuk Lymphoma. 2020;61(9):2221-2225.
27. Delia M, Pastore D, Carluccio P, et al. FLAG-Ida regimen as bridge therapy to allotransplantation in refractory / relapsed acute myeloid leukemia patients. Clin Lymphoma Myeloma Leuk. 2017;17(11):767-773.
28. Thol F, Döhner H, Ganser A. How I treat refractory and relapsed acute myeloid leukemia. Blood. 2024;143(1):11-20.
29. Wood H, Bourlon C, Kulasekararaj A, et al. Venetoclax-based non-intensive combinations successfully salvage molecular relapse of acute myeloid leukemia and are an important bridge to cellular therapy in relapsed / refractory disease-real-world data from a UK-wide programme. Blood.
2022;140(Suppl 1):9016-9018.
30. Tiong IS, Hiwase D, Abro EU, et al. A prospective phase 2 study
of venetoclax and low dose ara-C (VALDAC) to target rising molecular measurable residual disease and early relapse in acute myeloid leukemia. Blood. 2022;140(Suppl 1):1453-1455.
Haematologica | 110 January 2025
10